Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH): AST2303 tablets receive approval for drug clinical trials.
Ails (688578.SH) announced recently that the company has received the approval and issuance of the "Drug Clinical ..." by the National Medical Products Administration.
Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH) announced that the company recently received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration, approving the clinical trial of AST2303 tablets in adult patients with advanced non-small cell lung cancer carrying the EGFR C797S mutation. The announcement states that AST2303 tablets (ABK3376 tablets) are a highly selective and brain-permeable new generation EGFR oral small molecule inhibitor that can effectively inhibit the EGFRC797S mutation.
Related Articles
Bitcoin "hoarding whales" strategy (MSTR.US) secures a spot on the Nasdaq 100 MSCI Index still warns of potential removal in January.
Intel Corporation (INTC.US) is close to acquiring the AI chip startup company SambaNova for nearly $1.6 billion.
HK Bull/Bear Outstanding Qty Ratio(61:39) | December 13th
Bitcoin "hoarding whales" strategy (MSTR.US) secures a spot on the Nasdaq 100 MSCI Index still warns of potential removal in January.
Intel Corporation (INTC.US) is close to acquiring the AI chip startup company SambaNova for nearly $1.6 billion.
HK Bull/Bear Outstanding Qty Ratio(61:39) | December 13th
RECOMMEND
Valued At $10 Trillion, The Largest IPO In History Is Coming As SpaceX Announces Listing Plan
12/12/2025
Five Imperatives And Eight Tasks: Central Meeting Specifies Next Year’s Economic Work, Highlights Identified
12/12/2025
Over 100 New Listings In Hong Kong This Year As Total Fundraising Tops HKD 270 Billion, Eighteen “A+H” Dual Listings
12/12/2025
